Novel mechanistic and clinical implications concerning the safety of statin discontinuation

被引:10
|
作者
Jasinska-Stroschein, Magdalena [1 ]
Owczarek, Jacek [1 ]
Wejman, Irena [1 ]
Orszulak-Michalak, Daria [1 ]
机构
[1] Med Univ Lodz, Dept Biopharm, PL-90151 Lodz, Poland
关键词
HMG-CoA reductase inhibitors; withdrawal; pleiotropic effects; mechanism; SMOOTH-MUSCLE-CELLS; NITRIC-OXIDE SYNTHASE; C-REACTIVE-PROTEIN; COA REDUCTASE INHIBITORS; CORONARY-ARTERY-DISEASE; ACUTE MYOCARDIAL-INFARCTION; MATRIX METALLOPROTEINASES; RHO-GTPASE; UP-REGULATION; PPAR-GAMMA;
D O I
10.1016/S1734-1140(11)70602-8
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The beneficial effects of statins have been discussed widely, and their preventative role has been confirmed in cardiovascular disorders, primary and secondary prevention settings, and in asymptomatic subjects with a high cardiovascular risk. Despite these benefits, discontinuation of statins is frequent in cardiac patients and might be associated with adverse outcomes in several conditions involving acute coronary syndromes or acute stroke. In this review, we focus on the mechanistic background of statins that might contribute to such negative changes and that extend beyond cholesterol-lowering effects, including the so-called pleiotropic statin activity. In particular, findings regarding the detrimental impact of statin withdrawal on endothelial function, inflammation, platelet activity or AT1 signaling are discussed, along with the possible clinical implications for statin safety.
引用
收藏
页码:867 / 879
页数:13
相关论文
共 50 条
  • [1] Novel mechanistic and clinical implications concerning the safety of statin discontinuation
    Magdalena Jasińska-Stroschein
    Jacek Owczarek
    Irena Wejman
    Daria Orszulak-Michalak
    Pharmacological Reports, 2011, 63 : 867 - 879
  • [2] Statin Toxicity Mechanistic Insights and Clinical Implications
    Ward, Natalie C.
    Watts, Gerald F.
    Eckel, Robert H.
    CIRCULATION RESEARCH, 2019, 124 (02) : 328 - 350
  • [3] Statin safety and drug interactions: Clinical implications
    Bottorff, MB
    AMERICAN JOURNAL OF CARDIOLOGY, 2006, 97 (8A): : 27C - 31C
  • [4] Statin Treatment Non-adherence and Discontinuation: Clinical Implications and Potential Solutions
    Kim Phan
    Gomez, Yessica-Haydee
    Elbaz, Laura
    Daskalopoulou, Stella S.
    CURRENT PHARMACEUTICAL DESIGN, 2014, 20 (40) : 6314 - 6324
  • [5] Clinical implications for statin pleiotropy
    Liao, JK
    CURRENT OPINION IN LIPIDOLOGY, 2005, 16 (06) : 624 - 629
  • [6] Letter by Zhou et al Regarding Article, "Statin Toxicity: Mechanistic Insights and Clinical Implications"
    Zhou, Zhen
    Curtis, Andrea J.
    Breslin, Monique
    Nelson, Mark
    CIRCULATION RESEARCH, 2019, 124 (12) : E120 - E120
  • [7] Discontinuation of statin therapy and clinical outcome after ischemic stroke
    Colivicchi, Furio
    Bassi, Andrea
    Santini, Massimo
    Caltagirone, Carlo
    STROKE, 2007, 38 (10) : 2652 - 2657
  • [8] Response by Ward et al to Letter Regarding Article, "Statin Toxicity: Mechanistic Insights and Clinical Implications"
    Ward, N. C.
    Watts, G. F.
    Eckel, R. H.
    CIRCULATION RESEARCH, 2019, 124 (12) : E121 - E122
  • [9] Clinical implications of pharmacogenomics of statin treatment
    Mangravite, L. M.
    Thorn, C. F.
    Krauss, R. M.
    PHARMACOGENOMICS JOURNAL, 2006, 6 (06): : 360 - 374
  • [10] Clinical implications of pharmacogenomics of statin treatment
    L M Mangravite
    C F Thorn
    R M Krauss
    The Pharmacogenomics Journal, 2006, 6 : 360 - 374